<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02586233</url>
  </required_header>
  <id_info>
    <org_study_id>DS1040-A-U103</org_study_id>
    <nct_id>NCT02586233</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke</brief_title>
  <acronym>ASSENT</acronym>
  <official_title>A Phase 1b/2, Multi-Center, Double-Blind (Principal Investigators and Study Subjects Blinded, Sponsor Unblinded), Placebo-Controlled, Randomized, Single-Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2, double-blind (Principal Investigators and study subjects blinded,
      Sponsor unblinded), placebo-controlled, randomized, single-ascending dose, multi-center study
      to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of
      DS-1040b in subjects with Acute Ischemic Stroke (AIS).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and severity of adverse events</measure>
    <time_frame>from dose to 90 days post-dose</time_frame>
    <description>To count the number and severity of treatment emergent adverse events (TEAEs) within 90 days post dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter, area under concentration curve (AUC) of DS-1040b in plasma</measure>
    <time_frame>24 hours after dose</time_frame>
    <description>Pharmacokinetic parameter AUC of DS-1040b in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter, tmax of DS-1040b in plasma</measure>
    <time_frame>24 hours after dose</time_frame>
    <description>Pharmacokinetic parameter tmax of DS-1040b in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter, maximum concentration Cmax of DS-1040b in plasma</measure>
    <time_frame>24 hours after dose</time_frame>
    <description>Pharmacokinetic parameter Cmax of DS-1040b in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameter, amount of drug excreted in urine of DS-1040b in plasma</measure>
    <time_frame>24 hours after dose</time_frame>
    <description>Pharmacokinetic parameter amount of drug excreted in urine (Ae0-24) of DS-1040b in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>analysis for thrombin-activatable fibrinolysis inhibitor (TAFIa) antigen in plasma</measure>
    <time_frame>24 hours after dose</time_frame>
    <description>Pharmacodynamic analysis for thrombin-activatable fibrinolysis inhibitor (TAFIa) antigen in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>analysis for clot lysis in plasma</measure>
    <time_frame>24 hours after dose</time_frame>
    <description>Pharmacodynamic analysis for clot lysis (an exploratory biomarker) in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>analysis for D-dimer in plasma</measure>
    <time_frame>24 hours after dose</time_frame>
    <description>Pharmacodynamic analysis for D-dimer in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>analysis for total thrombin-activatable fibrinolysis inhibitor in plasma</measure>
    <time_frame>24 hours after dose</time_frame>
    <description>Pharmacodynamic analysis for total thrombin-activatable fibrinolysis inhibitor (total TAFIa) activity in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with AIS and a visible occlusion demonstrated on brain imaging at predose demonstrating recanalization at 24 hours.</measure>
    <time_frame>day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change by number and percentage in National Institute of Health Stroke Scale (NIHSS) score from predose to 30 days post-dose.</measure>
    <time_frame>day 0 (baseline) to day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change by number and percentage in modified Rankin Scale (mRS) score from baseline to day 90</measure>
    <time_frame>day 0 (baseline) to day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <condition>Thrombotic Disease</condition>
  <arm_group>
    <arm_group_label>DS-1040b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV infusion of DS-1040b ranging from 0.6mg to 9.6mg of DS-1040b.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DS-1040b</intervention_name>
    <description>IV infusion of DS-1040b</description>
    <arm_group_label>DS-1040b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo IV infusion</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18 years of age and older.

          -  Subjects have a clinical diagnosis of acute ischemic stroke (including lacunar stroke)
             supported by computed topography or magnetic resonance imaging.

          -  Subjects have stroke symptoms onset within 4.5 to 12 hours before initiation of study
             drug administration. For subjects with a wake-up stroke, symptoms onset time refers to
             the last time the subject was known to be well.

          -  Subjects have a NIHSS score of â‰¥ 2.

          -  Subjects, (or their legally authorized representative-where applicable and based on
             country-specific practice), must give written informed consent to participate in the
             study prior to participating in any study-related procedures. A separate written
             informed consent is required for collecting a blood sample for genotyping.

        Exclusion Criteria:

        - Subjects have been treated or are anticipated to be treated with tissue plasminogen
        activator and/or endovascular thrombectomy during current stroke.

        Eligible subjects declining these treatments can be enrolled to this study.

          -  Subjects have evidence of intracranial hemorrhage on non-contrast computed tomography
             (CT) (or magnetic resonance [MR]).

          -  Subjects have symptoms of subarachnoid hemorrhage, even with normal CT.

          -  Subjects have an Alberta Stroke Program Early CT Score (ASPECTS) &lt; 6.

          -  Subjects have prior non-traumatic intracranial hemorrhage (excluding microhemorrahages
             observed in imaging).

          -  Subjects have known arteriovenous malformation or aneurysm.

          -  Subjects have evidence of active bleeding.

          -  Subjects have platelet count &lt; 100,000.

          -  Subjects have International Normalized Ratio &gt; 1.7.

          -  Subjects have used unfractionated heparin within 24 hours prior to treatment and have
             an elevated partial thromboplastin time.

          -  Subjects have used a nonvitamin K antagonist oral anticoagulant such as dabigatran,
             rivaroxaban, apixaban, or other factor Xa inhibitors within 24 hours prior to
             treatment.

          -  Subjects have used fondaparinux or low molecular weight heparin at an anticoagulation
             dose within 24 hours prior to treatment.

          -  Subjects with anticipated use of an anticoagulation dose of heparin, or fondaparinux
             or low molecular weight heparin, or nonvitamin K antagonist oral anticoagulant such as
             dabigatran, rivaroxaban, apixaban, or other factor Xa inhibitors within 48 hours of
             randomization. Low dose heparin or low molecular weight heparin at a preventive dose
             are allowed from 24 hours after treatment start and after confirmation of no
             intracranial bleeding on the 24-hours repeat brain imaging.

          -  Subjects have blood pressure &gt; 185/110 mmHg, or require aggressive medication to
             maintain blood pressure below this limit (routine medical treatment is allowed to
             lower the blood pressure below this limit).

          -  Subjects have had intracranial surgery, clinically significant head trauma (in the
             opinion of Principal Investigator), Alteplase treatment, or a previous stroke within 1
             month.

          -  Subjects have had major surgery within 14 days.

          -  Subjects have had gastrointestinal or genitourinary bleeding in the last 21 days.

          -  Subjects have had a lumbar puncture (or epidural steroid injection) within 14 days.

          -  Subjects have a preexisting disability classified by mRS &gt; 2.

          -  Subjects have an estimated glomerular filtration rate (using Modification of Diet in
             Renal Disease equation) &lt; 60 mL/min/1.73 m2.

          -  Subjects have baseline hemoglobin &lt; 10.5 g/dL.

          -  Subjects have a positive pregnancy test. Serum or urine pregnancy tests will be
             performed (according to site-specific practice) in women of childbearing potential
             (childbearing potential is assumed in women up to 55 years of age).

          -  Subject is currently participating in another investigational study or has
             participated in an investigational drug study within 30 days or 5 half-lives of that
             investigational drug prior to administration of the study drug.

          -  Subject is an employee or an immediate family member of an employee of the Sponsor,
             the CRO ((INC Research), or the Site.

          -  Any other reason, in the opinion of the Investigator, which precludes subject
             participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Leader, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>INC Research</last_name>
    <email>DS1040-A-U103@incresearch.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of South Alabama USA Health System</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>251-445-8292</phone>
      <email>scordina@health.southalabama.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center Stroke Network</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>310-794-0600</phone>
      <email>starkman@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Center at Harbor- UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>310-222-7930</phone>
      <email>tgdevlin@bellsouth.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UC Health Memorial Hospital</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>719-365-2259</phone>
      <email>janice.miller@uchealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University at Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>312-563-2208</phone>
      <email>rima_dafer@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>859-218-5443</phone>
      <email>cpetti@email.uky.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>313-916-9107</phone>
      <email>Dmille12@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JFK Neuroscience Institute</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08820</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>732-321-7950</phone>
      <email>jkirmani@jfkhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>919-684-8969</phone>
      <email>carmelo.graffagnino@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OSU - Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>614-685-7234</phone>
      <email>Yousef.Hannawi@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>503-494-7223</phone>
      <email>clarkw@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>717-531-3828</phone>
      <email>kub16@psu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Palmetto Health, USC School of Medicine</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>803-545-6078</phone>
      <email>Souvik.Sen@uscmed.sc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chattanooga Center for Neurologic Research</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>423-413-2413</phone>
      <email>tgdevlin@bellsouth.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>713-441-7161</phone>
      <email>jjvolpi@tmhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre for Neuroscience Innovation, Calvary Wakefield Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital Neurology Dept.</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <email>timothy.kleinig@sa.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+61 395946666</phone>
      <email>thanh.phan@monash.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+61 407356869</phone>
      <email>bruce.campbell@mh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+61 407356869</phone>
      <email>bruce.campbell@mh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>St. Annes University Hospital</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+420 732561104</phone>
      <email>michal.reif@fnusa.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava Neurologicka</name>
      <address>
        <city>Ostrava Poruba</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Vitkovicka nemocnice a.s. Zaluzanskeho</name>
      <address>
        <city>Ostrava Vitkovice</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+420 606134051</phone>
      <email>daniel.vaclavik@vtn.agel.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mestska nemocnice Ostrava</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>General Faculty Hospital</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHRU BesanÃ§on - HÃ´pital Jean Minjoz</name>
      <address>
        <city>BesanÃ§on</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>HÃ´pital Pellegrin - CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+33 556795520</phone>
      <email>igor.sibon@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - HÃ´pital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Altenburger Land</name>
      <address>
        <city>Altenburg</city>
        <zip>04600</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+49 3447521380</phone>
      <email>joerg.berrouschot@klinikum-altenburgerland.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurologische Universit Autsklinik</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universittsklinikum Essen AR Klinik fr Neurologie</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+49 2017236501</phone>
      <email>martin.koehrmann@uk-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universitat</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+49 69630187745</phone>
      <email>waltraud.pfeilschifter@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt Hoechst GmbH</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen (UKT)</name>
      <address>
        <city>TÃ¼bingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ospedale di Citta di Castello</name>
      <address>
        <city>CittÃ  di Castello</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+39 0758509654</phone>
      <phone_ext>278</phone_ext>
      <email>stefano.ricci@uslumbria1.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Branca Largo Unita d'Italia</name>
      <address>
        <city>Gubbio</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+39 0759270418</phone>
      <email>tatiana.mazzoli@uslumbria1.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Istituto Neurologico Nazionale</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Guglielmo da Saliceto Via Taverna</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+39 052330330724</phone>
      <email>d.guidetti@ausl.pu.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedaliero di Albenga - Pietra Ligure Dept Neurology</name>
      <address>
        <city>Pietra Ligure</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+39 196232600</phone>
      <email>t.tassinari@asl2.liguria.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+39 050992443</phone>
      <email>u.bonuccelli@med.unipi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Borgo Trento</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <email>kimgm@skku.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+82 317877467</phone>
      <email>braindocbae@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Svet zdravia, a.s. Nemocnica</name>
      <address>
        <city>Galanta</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Liptovska nemocnica s poliklinikou</name>
      <address>
        <city>LiptovskÃ½ MikulÃ¡Å¡</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Svet zdravia a.s.,Vseobecna nemocnica Rimavska Sobota</name>
      <address>
        <city>RimavskÃ¡ Sobota</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+421 475616651</phone>
      <email>judita.herenyiova@svetzdravia.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NsP Spisska Nova Ves</name>
      <address>
        <city>SpiÅ¡skÃ¡ NovÃ¡ Ves</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Fakultna Nemocnica Trnava</name>
      <address>
        <city>Trnava</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Fakultna Nemocnica s Poliklinikou Zilina</name>
      <address>
        <city>Å½ilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital de la santa creu i sant pau C</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+34 935537143</phone>
      <email>jmarti@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <email>cmolina@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General san Pedro De Alcantara</name>
      <address>
        <city>CÃ¡ceres</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+34 917277444</phone>
      <email>exuperio.diez@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+34 981951086</phone>
      <email>manyanez@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+34 686995416</phone>
      <email>soledad.perez.sanchez@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+34 955012593</phone>
      <email>pmoniche@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+34 983420000</phone>
      <email>jfarenillas@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Lozano Blesa de Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+34 976765700</phone>
      <email>carlos.tejero@sen.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+886 422062121</phone>
      <phone_ext>7192</phone_ext>
      <email>d2742@mail.cmuh.org.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+866 62353535</phone>
      <email>Ichih@mail.ncku.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <email>jsjeng@ntu.edu.tw</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital-Linkou</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+866 33281200</phone>
      <email>julianseak@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+44 1412012494</phone>
      <email>k.muir@clinmed.gla.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University College Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+44 2031087529</phone>
      <email>richard.perry@uclh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>(CGMHLK) Ward 41, Level 4, Leazes Wing</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Salford Royal Hospital</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+44 01612060623</phone>
      <email>craig.smith-2@manchester.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital</name>
      <address>
        <city>Stoke-on-Trent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+44 1782552313</phone>
      <email>christine.roffe@northstaffs.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Ischemic Stroke in the anterior circulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

